Company announces first phase 1 trial of MERS antibody treatment
SAB Biotherapeutics, Inc., of Sioux Falls, S.D., announced today that its experimental human antibody treatment for MERS-CoV—called SAB-301—has entered human trials, the first potential treatment for the disease to do so.